ANI Pharmaceuticals Reports 53.1% Revenue Growth to $211.4 Million in Latest Quarter

ANI Pharmaceuticals, Inc. reported significant financial growth in its latest quarterly results, with net revenues reaching $211.4 million for the three months ended June 30, 2025, compared to $138.0 million for the same period in 2024, marking a 53.1% increase. The company's net income for the quarter was $8.5 million, a notable recovery from a net loss of $2.3 million in the prior year. For the first half of 2025, ANI's revenues totaled $408.5 million, up 48.3% from $275.5 million in the same period last year, driven by strong sales in its Rare Disease and Brands segment, particularly from Cortrophin Gel and newly acquired products ILUVIEN and YUTIQ.

The substantial revenue growth can be attributed to the successful integration of Alimera Sciences, which ANI acquired in September 2024. This acquisition added two new products to ANI's portfolio, contributing to a 111.3% increase in revenues from the Rare Disease segment, which totaled $104.0 million in the latest quarter. Additionally, the Generics and Other segment saw a 19.5% increase in revenues, reaching $94.2 million, primarily due to the launch of new products and increased sales volumes.

Operating expenses also rose, with total operating expenses for the second quarter of 2025 amounting to $197.5 million, up from $132.9 million in the same quarter of 2024. This increase was driven by higher costs in research and development, as well as selling, general, and administrative expenses, which rose by 54.8% to $81.8 million. The company is investing heavily in expanding its Rare Disease sales and marketing infrastructure, which includes a new ophthalmology sales team.

In terms of operational metrics, ANI's cash and cash equivalents increased to $217.8 million as of June 30, 2025, up from $144.9 million at the end of 2024. The company also reported a total employee headcount of 1,200, reflecting its growth strategy and expansion efforts. Looking ahead, ANI anticipates continued growth driven by its Rare Disease and Brands segment, with plans to further expand its product offerings and market presence, particularly in international markets where Alimera has established operations. The company is also evaluating potential acquisitions to complement its existing portfolio and capabilities.